Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical Phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on the Nasdaq First North Growth Market (ticker "PROMO").
Location: Sweden, Solna kommun
Employees: 11-50
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Midroc New... | midroc.se |
| - | Chalmers V... | chalmersve... |
Mentions in press and media 10
| Date | Title | Description |
| 15.05.2024 | Jenni Björnulfson appointed as new CFO of Peptonic Medical | Jenni Björnulfson appointed as new CFO of Peptonic Medical Wed, May 15, 2024 14:00 CET Report this content Peptonic Medical AB (publ) ("Peptonic") announces the appointment of Jenni Björnulfson as the company's new Chief Financial... |
| 12.04.2024 | Notice of Annual General Meeting in Moberg Pharma AB (publ) | Notice of Annual General Meeting in Moberg Pharma AB (publ) Fri, Apr 12, 2024 08:00 CET Report this content Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426, (the “Company”) are hereby convened to the Annual General Meeting on ... |
| 27.02.2023 | Promore Pharma Reaches the Clean File Milestone in its Phase II Clinical Trial with Ensereptide | STOCKHOLM, SWEDEN / ACCESSWIRE / February 27, 2023 / Promore Pharma PROMO (FRA:8T0) STOCKHOLM, 27 February, 2023 -- Promore Pharma AB announces today that the Clean File milestone has been achieved in the PHSU05 clinical trial. The publicat... |
| 24.11.2022 | Invitation to Conference Call Regarding Promore Pharma’s Interim Report for the Third Quarter 2022 | STOCKHOLM, SE / ACCESSWIRE / November 24, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, 24 November 2022 - Promore Pharma AB (publ) publishes its interim report for the third quarter 2022 on 29 November 2022. The day after, the 30 N... |
| 23.11.2022 | Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma | STOCKHOLM, SE / ACCESSWIRE / November 23, 2022 / Promore Pharma PROMO (FRA:8T0) STOCKHOLM, 23 November 2022 - Promore Pharma AB (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2023, which wi... |
| 17.05.2022 | Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022 | STOCKHOLM, SWEDEN / ACCESSWIRE / May 17, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0) Promore Pharma AB, reg. no. 556639-6809, held its AGM on Tuesday, 17 May 2022. The main resolutions passed at the meeting were as follows. More detailed in... |
| 13.05.2022 | Invitation to Conference Call Regarding Promore Pharma’s Interim Report for the First Quarter 2022 | STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, 13 May 2022 - Promore Pharma AB (publ) publishes its interim report for the first quarter 2022 on 17 May 2022. The same day the company will host... |
| 12.04.2022 | Notice of Annual General Meeting Promore Pharma AB (publ) | STOCKHOLM, SWEDEN / ACCESSWIRE / April 12, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0) The Annual General Meeting of Promore Pharma AB (publ) will be held on Tuesday, 17 May 2022 at 2 pm, in the premises of Wennergren Center, Biblioteket, fl... |
| 28.04.2021 | PROMORE PHARMA AB (PUBL) Promore Pharma AB : (publ) - NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL) | Unofficial English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence. Due to the extraordinary situation as a result of Covid-... |
| 07.05.2018 | Allergan aesthetics chief David Moatazedi becomes CEO of Evolus; CARB-X invests $6.2M into Melinta's next-gen antibiotics | David Moatazedi → Allergan aesthetics chief David Moatazedi is leaving to take the helm of Evolus, a much smaller biotech developing a rival to Botox. Evolus’ new drug DWP-450 (PrabotulinumtoxinA) is under review. Moata... |